{"disease":{"id":"urticaria-chronic","name":"urticaria chronic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04583475","title":"Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria","phase":"","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT05936567","title":"Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT00783354","title":"A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT06931405","title":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT06736262","title":"A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":67,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03858634","title":"A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT06865651","title":"Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05916937","title":"Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Simon Francis Thomsen","has_results":false},{"nct_id":"NCT05960708","title":"A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT03111628","title":"Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT03632291","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"United BioPharma","has_results":false},{"nct_id":"NCT05461456","title":"Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"OrchestratePharma GmbH","has_results":false},{"nct_id":"NCT03151902","title":"Detection of Viral Particels in Urticaria Patients","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"HaEmek Medical Center, Israel","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}